Article info

Download PDFPDF

Original research
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma

Authors

  1. Correspondence to Professor Jonathan S Cebon; j.cebon{at}onjcri.org.au
View Full Text

Citation

Cebon JS, Gore M, Thompson JF, et al
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma

Publication history

  • Accepted March 3, 2020
  • First published April 20, 2020.
Online issue publication 
April 20, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.